Ticagrelor Tablet
Product Images NDC 73190-003

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 73190-003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (003 60)

Each tablet contains 60 mg of ticagrelor. The usual adult dosage should be taken as indicated on the package insert. It is important to keep this medication out of reach of children. Store at temperatures between 15°C to 30°C (56°F to 86°F). This medication is manufactured for Avkare in Pulaski, TN, and dispensed by MSN Pharmaceuticals Inc. in Piscataway, NJ. Remember to provide the accompanying Medication Guide to each patient.*

FDA Label Image

Tica-tabs-fig-01 (Tica Tabs Fig 01)

FDA Label Image

Tica-tabs-fig-02 (Tica Tabs Fig 02)

FDA Label Image

Tica-tabs-fig-03 (Tica Tabs Fig 03)

FDA Label Image

Tica-tabs-fig-04 (Tica Tabs Fig 04)

FDA Label Image

Tica-tabs-fig-05 (Tica Tabs Fig 05)

FDA Label Image

Tica-tabs-fig-06 (Tica Tabs Fig 06)

FDA Label Image

Tica-tabs-fig-07 (Tica Tabs Fig 07)

FDA Label Image

Tica-tabs-fig-08 (Tica Tabs Fig 08)

This text provides information on the effect and confidence intervals for various medications based on CYP3A4 inhibitors, inducers, and other relevant factors. It includes recommendations such as avoiding concomitant use with strong CYP3A4 inhibitors like Ketoconazole, while no dose adjustment is needed for moderate CYP3A4 inhibitors such as Diltiazem. Additionally, it provides instructions for several specific medications and their usage based on different criteria.*

FDA Label Image

Tica-tabs-fig-09 (Tica Tabs Fig 09)

This information provides the interaction between Ticagrelor and different drugs, including dose adjustments and recommendations. It outlines the effects, recommended doses, and adjustments for drugs like Simvastatin, Atorvastatin, Lovonorgestrol, Estradiol, Tolbutamide, Digoxin, and Cyclosporine when taken with Ticagrelor at various doses and frequencies. For each drug, the text indicates whether a dose adjustment is needed or not when combined with Ticagrelor.*

FDA Label Image

Tica-tabs-fig-10 (Tica Tabs Fig 10)

FDA Label Image

Tica-tabs-fig-11 (Tica Tabs Fig 11)

FDA Label Image

Tica-tabs-fig-12 (Tica Tabs Fig 12)

FDA Label Image

Tica-tabs-fig-13 (Tica Tabs Fig 13)

FDA Label Image

Tica-tabs-fig-14 (Tica Tabs Fig 14)

FDA Label Image

Tica-tabs-fig-15 (Tica Tabs Fig 15)

FDA Label Image

Tica-tabs-fig-16 (Tica Tabs Fig 16)

FDA Label Image

Tica-tabs-fig-17 (Tica Tabs Fig 17)

FDA Label Image

Tica-tabs-fig-18 (Tica Tabs Fig 18)

This is a statistical analysis of a study comparing the effects of Ticagrelor versus Placebo. The analysis includes data on patient characteristics such as age, sex, race, weight, BMI, geographic region, and medical history. The study also provides information on the efficacy of Ticagrelor compared to Placebo, with data presented in percentages and hazard ratios with corresponding confidence intervals. The analysis evaluates the impact of Ticagrelor on different subgroups of patients based on various factors.*

FDA Label Image

Tica-tabs-structure (Tica Tabs Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.